# Early Intervention With Acalabrutinib in Patients With High Risk CLL

> **NCT04660045** · PHASE2 · WITHDRAWN · sponsor: **Weill Medical College of Cornell University**

## Conditions studied

- Chronic Lymphocytic Leukemia
- CLL/SLL

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04660045
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05
- **Primary completion:** 2026-01
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company supplying drug/funding ceased support.
- **Last updated:** 2022-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04660045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04660045, "Early Intervention With Acalabrutinib in Patients With High Risk CLL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04660045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*